Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Surufatinib in Moderate Renal Impairment
NCT04755088Phase 1Completed
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Feb 2021
- Primary completion
- Aug 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of surufatinib in neuroendocrine tumors (NETs) (2 arms), sponsored by Hutchison MediPharma (HMP). Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at Day 6, Area Under the Concentration-Time Curve From Time Zero to Infinity at Day 6 and 1 more. Started Feb 2021; status: completed.
02
Drugs
surufatinib
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT04755088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755088.